If you’re hearing about Ozempic, Wegovy, or Rybelsus, chances are you already know a thing or two about semaglutide. These popular weight loss and antidiabetic drugs use semaglutide as their base formula, but what exactly is it? How does it work? If your doctor has written you a prescription that includes either of these drugs, this article sums up everything you need to know about how semaglutide works, its benefits, side effects, and how much it costs.
What is semaglutide and how does it work?
Semaglutide is the active substance in Ozempic, Wegovy, and Rybelsus. It is used to manage blood sugar in people with type 2 diabetes and to support weight loss in those who are obese or overweight with one weight-related health concern. Many doctors also prescribe it off-label, such as for polycystic ovary syndrome (PCOS), which may require consistent monitoring to ensure safe use.
It belongs to a class of drugs called GLP-1 receptor agonists, which mimic a natural hormone in the body known as glucagon-like peptide-1 (GLP-1). Semaglutide is 94% identical to human GLP-1. After subcutaneous injection, semaglutide activates GLP-1 receptors in the gastrointestinal tract, pancreas, and brain. Not only does it mimic GLP-1 to suppress appetite, but it also interacts with the GLP-1 receptors in the hypothalamus to make you feel less hungry and reduce the urge to eat immediately.
What medication brands contain semaglutide?
Four brand-name prescriptions contain semaglutide — Ozempic, Wegovy, Wegovy tablets, and Rybelsus, often referred to as the oral version of Ozempic.
Ozempic
Ozempic was approved by the FDA in 2017 to improve blood sugar control in people with type 2 diabetes. It’s also prescribed to reduce the risk of heart complications in those with type 2 diabetes with co-existing cardiovascular diseases.
Wegovy
Wegovy was medically cleared by the FDA in 2021 to manage obesity or overweight in adults and children at least 12 years old. Like Ozempic, it’s also prescribed to help prevent cardiovascular complications in those with weight problems who are also diagnosed with heart disorders.
Rybelsus
Rybelsus is the first FDA-approved oral semaglutide for treating diabetes in adults. Because it contains the same active substance as Ozempic, people often call it “Ozempic in pill form.” It was approved by the FDA in 2019 and is recommended alongside diet and exercise.
Wegovy tablets
The pill version of Wegovy was approved by the FDA in 2025 to manage obesity or overweight in adults. It’s also prescribed to help prevent cardiovascular complications in those with weight problems who are also diagnosed with heart disorders. Unlike the injectable formulation, Wegovy tablets are not approved for use in pediatric patients aged 12 years and older.
Generic semaglutide
Canada became the first G7 country to approve generic semaglutide in 2026. Health Canada authorized the first generic semaglutide injection from Dr. Reddy’s Laboratories in April 2026, followed shortly by approvals for Apotex’s generic version. Both are indicated for the treatment of type 2 diabetes, similar to Ozempic.
If you require semaglutide treatment for diabetes or weight loss, your doctor will review your health history to determine which of the four brands is best suited to your needs.
What is the dosing schedule for semaglutide?
Semaglutide products are available in different formulations, each with its own dosing schedule. Here’s how the various semaglutide medications are typically dosed:
Ozempic dosage chart
| Weeks | Ozempic for diabetes |
| Weeks 1-4 | 0.25 mg once weekly (initial dose) |
| Weeks 5-8 | 0.5 mg once weekly |
| Weeks 9-12 | 1 mg once weekly |
| Weeks 13-16 | 2 mg once weekly (maximum dose) |
Wegovy dosage chart
| Weeks | Wegovy for weight loss |
| Weeks 1-4 | 0.25 mg once a week (initial dose) |
| Weeks 5-8 | 0.5 mg once a week |
| Weeks 9-12 | 1 mg once a week |
| Weeks 13-16 | 1.7 mg once a week |
| Weeks 17-20 or longer | 2.4 mg once a week (recommended maintenance dose) |
| Week 21 and onward | 7.2 mg once a week (Wegovy HD is a higher-dose version prescribed for adults who have not achieved their desired weight loss after at least four weeks on the standard 2.4 mg maintenance dose. This is also the maximum maintenance dose) |
Rybelsus dosage chart
Rybelsus comes in two formulations that differ based on recommended dosages. R1 is available in 3 mg, 7 mg, and 14 mg dosages, while R2 comes in 1.5 mg, 4 mg, and 9 mg dosages. It’s taken once daily on an empty stomach with a small sip of plain water (no more than 4 ounces). Wait at least 30 minutes before eating, drinking, or taking other medications. Do not crush, split, or chew the tablet. Always swallow it whole.
| Days | Rybelsus R1 | Rybelsus R2 |
| Days 1 to 30 | 3 mg orally once daily (initial dose) | 1.5 mg orally once daily (initial dose) |
| Days 31 to 60 | 7 mg orally once daily (recommended maintenance dose) | 4 mg orally once daily (recommended maintenance dose) |
| Days 61 onward | 14 mg orally once daily (highest dose) | 9 mg orally once daily (highest dose) |
Wegovy tablet dosage chart
Similar to Rybelsus, the Wegovy pill is taken once daily on an empty stomach with a small sip of plain water (no more than 4 ounces). Wait at least 30 minutes before eating, drinking, or taking other medications. Do not crush, split, or chew the tablet. Always swallow it whole.
| Days | Wegovy tablets for weight loss |
| Days 1 to 30 | 1.5 mg orally once daily (initial dose) |
| Days 31 to 60 | 4 mg orally once daily |
| Days 61-90 | 9 mg orally once daily |
| Days 91 and onward | 25 mg orally once daily (recommended maintenance dose) |
How effective is semaglutide for weight loss and diabetes?
Several clinical trials and studies have proven that Ozempic, Wegovy, and Rybelsus effectively promote weight loss and lower blood sugar levels. Outcomes vary based on their approved uses.
Semaglutide for weight loss
Based on clinical trials, semaglutide can produce roughly 10% to 17% body-weight loss for many adults when used at the obesity dose of 2.4 mg once weekly and paired with diet and physical activity. In practical terms, someone starting at 100 kg might lose about 10 to 17 kg on average. Some people lose less, some lose more, and a meaningful minority in trials lost 20% or more.
The strongest evidence is the STEP 1 trial, published in The New England Journal of Medicine. Adults with overweight or obesity, but without diabetes, took semaglutide 2.4 mg weekly for 68 weeks. The semaglutide group lost an average of 14.9% of body weight, compared with 2.4% in the placebo group.
People with type 2 diabetes usually lose less weight on semaglutide than people without diabetes. In STEP 2, adults with overweight or obesity and type 2 diabetes lost about 9.6% with semaglutide 2.4 mg, compared with 3.4% on placebo. So, for a person with diabetes, a more realistic average expectation may be closer to 8% to 10%, though individual results vary.
When semaglutide is combined with a more intensive lifestyle program, the weight loss can be slightly higher. In STEP 3, semaglutide was added to intensive behavioral therapy and an initial low-calorie diet. Participants lost about 16% of body weight over 68 weeks, compared with 5.7% in the placebo group. This supports the idea that semaglutide works best when paired with structured nutrition and behavior support.
In the recent STEP UP trial, adults with obesity who received 7.2 mg semaglutide once weekly lost an average of about 18.7% of their body weight after 72 weeks, compared with roughly 15.6% on the standard 2.4 mg dose and 3.9% with placebo.
The STEP 4 trial looked at what happens when people stop. Everyone first received semaglutide for 20 weeks. After that, some continued on semaglutide, and others switched to a placebo. Those who continued kept losing weight, while those who stopped regained weight. From week 20 to week 68, the continued-semaglutide group lost an additional 7.9%, while the placebo-switched group regained 6.9%. This suggests semaglutide behaves more like a long-term treatment than a short course.
Longer-term data are also available. In STEP 5, adults were followed for 104 weeks, or about two years. Semaglutide produced sustained weight loss, with an average loss of around 15.2% at two years, while placebo weight loss was much smaller.
Semaglutide has also been compared with older GLP-1 weight-loss medicines. In STEP 8, weekly semaglutide 2.4 mg was compared with daily liraglutide 3.0 mg. Semaglutide produced substantially greater weight loss over 68 weeks, with reported average loss around 15.8%, compared with about 6.4% for liraglutide.
There is also adolescent data. In STEP TEENS, adolescents with obesity received semaglutide 2.4 mg weekly plus lifestyle intervention. The study found a large reduction in BMI, with reports describing about a 16% to 17% BMI reduction compared with placebo.
Oral semaglutide has been studied as well. In OASIS 4, participants taking 25 mg oral semaglutide lost about 13.6% to 14% of body weight over roughly 64 weeks, compared with about 2% with placebo plus lifestyle intervention. Nearly 30% of participants achieved at least 20% weight loss, which is a remarkably high response rate for an oral obesity medication.
Semaglutide for type 2 diabetes
Clinical trials consistently show that semaglutide is highly effective at lowering blood sugar in type 2 diabetes, typically reducing HbA1c by about 1.0% to 2.2%, depending on dose and baseline glucose levels.
In SUSTAIN 1, patients on weekly semaglutide monotherapy saw HbA1c reductions of about 1.5% after 30 weeks. In SUSTAIN 2, semaglutide lowered HbA1c by roughly 1.3%-1.6% over 56 weeks, outperforming sitagliptin. In SUSTAIN 3, semaglutide reduced HbA1c by about 1.5% after 56 weeks, exceeding exenatide ER. In SUSTAIN 4, semaglutide achieved about 1.2%-1.6% HbA1c reduction over 30 weeks, outperforming insulin glargine.
In SUSTAIN 7, semaglutide lowered HbA1c by approximately 1.5%-1.8% after 40 weeks, compared with 1.1%-1.4% for dulaglutide. More recently, the SUSTAIN FORTE trial showed that 2 mg weekly semaglutide reduced HbA1c by about 2.2% after 40 weeks, compared with about 1.9% using the 1.0 mg dose, demonstrating stronger glucose control at higher dosing.
How long does it take for semaglutide to work?
Semaglutide usually starts affecting appetite and blood sugar within the first 1-2 weeks, but the full effects develop gradually because the dose is intentionally increased slowly over several months to reduce side effects.
For type 2 diabetes, blood sugar improvements can often be seen within the first few weeks, with meaningful HbA1c reductions becoming clearer by about 8-12 weeks. Most diabetes trials measured the major effect after about 30-40 weeks, where HbA1c reductions of roughly 1%-2% were typically reached.
For weight loss, people often notice reduced hunger and smaller food intake within the first few weeks, but visible weight loss usually becomes more noticeable after about 1-3 months. In the major STEP obesity trials, weight loss continued steadily for nearly the entire study duration, with the largest effects seen around 60-72 weeks. Average losses of around 15%-21% were generally achieved after about 1 to 1.5 years, depending on dose.
To get the best results with semaglutide, doctors recommend combining the medication with long-term lifestyle changes. Eating balanced meals with enough protein, fiber, vegetables, and whole foods can help improve weight loss, blood sugar control, and reduce side effects like nausea. Many patients also find it helpful to avoid large meals, greasy foods, and excessive alcohol while adjusting to the medication.
Regular physical activity is equally important. Most guidelines recommend at least 150 minutes of moderate exercise per week, such as brisk walking, cycling, swimming, or strength training. Exercise not only supports additional weight loss but also helps preserve muscle mass, improve insulin sensitivity, and maintain results over time. Your doctor or dietitian can help create a nutrition and activity plan that fits your health goals and medical needs.
What are the side effects of semaglutide?
Using semaglutide may cause side effects. Some of the common ones include:
-
- nausea
- vomiting
- diarrhea
- constipation
- stomach pain
- fatigue
- headache
Injection site reactions may occur in those using semaglutide shots. Symptoms of skin irritation include redness, swelling, and pain.
In rare cases, taking a semaglutide injection or pill may cause severe side effects that include:
-
- pancreatitis
- gallbladder problems
- kidney issues
- severe low blood sugar levels
- severe stomach-related symptoms
- pulmonary aspiration
- diabetes-related vision loss
Common symptoms like nausea often improve with time. If side effects persist after several weeks of treatment, inform your doctor so they can examine your condition.
How much does semaglutide cost?
Branded semaglutide can be pretty expensive, especially if you don’t have insurance. Below are the average costs of semaglutide brands in the US versus their prices in Canada.
| Average Costs | Ozempic | Wegovy | Rybelsus | Generic Semaglutide |
|---|---|---|---|---|
| In the US | ~$1,027 | ~$1,349 | ~$1,027 | Not available in the US |
| In Canada | $329.95 | $599 | $298 | $199.99 |
Who should not take semaglutide?
People with the following conditions are advised against using semaglutide because of the possible severe risks.
-
- patients with type 1 diabetes
- people with a personal or family history of medullary thyroid carcinoma (MTC)
- people diagnosed with multiple endocrine neoplasia Type 2 (MEN 2) syndrome
- people with a history of suicidal attempts or current suicidal ideation
If the benefits outweigh the risks, semaglutide may be used in the following patients, but they require close medical monitoring.
-
- People who have undergone bariatric surgery, since the risk of gastrointestinal complications is high
- Those who take other oral drugs to manage another condition, because semaglutide slows gastric emptying and may interfere with the absorption of other oral medications.
Lastly, there’s also the risk of regaining weight if you stop taking semaglutide. Based on the STEP 1 trial study, participants regained up to two-thirds of the weight they had initially lost after discontinuing semaglutide.
Bottom line
Semaglutide has quickly become one of the most important medications in modern treatment for obesity and type 2 diabetes, offering significant improvements in blood sugar control, weight loss, and overall metabolic health. In major clinical trials, patients using semaglutide for weight management lost an average of about 15% of their body weight over 68 weeks, while newer higher-dose studies have reported average losses nearly reaching 20%.
For people with type 2 diabetes, semaglutide has also shown strong blood sugar improvements, with many studies reporting HbA1c reductions of around 1% to 2% within 30 to 40 weeks. These benefits can lower the risk of complications linked to obesity and diabetes, including cardiovascular disease, insulin resistance, and fatty liver disease. Although semaglutide is not a cure and works best alongside healthy lifestyle changes, the growing body of research suggests it is one of the most effective long-term medical treatments currently available for metabolic health.
Frequently Asked Questions
Articles you may also be interested in
Sources
BusinessWire. (2026, May 16). Dr. Reddy’s Laboratories Launches its Generic Semaglutide Injection in Canada. Business Wire. https://www.businesswire.com/news/home/20260515689507/en/Dr.-Reddys-Laboratories-Launches-its-Generic-Semaglutide-Injection-in-Canada
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., Garvey, W. T., & Investigators, S. 3. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA, 325(14), 1403. https://doi.org/10.1001/jama.2021.1831
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., Investigators, S. 4., Friberg, M., Sjödin, A., Dicker, D., Segal, G., . . . Warren, M. L. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414. https://doi.org/10.1001/jama.2021.3224
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., & Group, T. S. 5. S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., Investigators, S. 8., Arauz-Pacheco, C., Cannon, K., Downey, H. J., Fitz-Patrick, D., Geohas, J., Gerety, G., Gilbert, J., Hollander, P., Klein, E., . . . Toth, P. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA, 327(2), 138. https://doi.org/10.1001/jama.2021.23619
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022). Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine, 387(24), 2245–2257. https://doi.org/10.1056/nejmoa2208601
Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. D., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969
OASIS 4: Significant weight loss with oral semaglutide comparable with High-Dose, SC versions – American College of Cardiology. (2025, September 24). American College of Cardiology. https://www.acc.org/latest-in-cardiology/journal-scans/2025/09/24/16/40/oasis-4
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949–963. https://doi.org/10.1016/s2213-8587(25)00226-8
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021). Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology, 9(9), 563–574. https://doi.org/10.1016/s2213-8587(21)00174-1
Sorli, C., Harashima, S., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251–260. https://doi.org/10.1016/s2213-8587(17)30013-x
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The Lancet Diabetes & Endocrinology, 5(5), 341–354. https://doi.org/10.1016/s2213-8587(17)30092-x
Aroda, V. R., Bain, S. C., Cariou, B., Pileti?, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology, 5(5), 355–366. https://doi.org/10.1016/s2213-8587(17)30085-2
Proa, S. E. (2002). Antes bien, la noche: Entresueños de la música pensante. A Parte Rei: Revista De Filosofía, 41(24), 9–266. https://doi.org/10.2337/dc17-0417
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275–286. https://doi.org/10.1016/s2213-8587(18)30024-x
